NPRL3

Across TCGA pan-cancer cohorts, NPRL3 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated NPRL3 data layer compared with 3 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NPRL3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPRL3 expression acts as an unfavorable survival marker, although some lineages such as UVM and BRCA show a favorable association.

LIHC, LUAD, and COAD are the cancer types where NPRL3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.452	0.627	<.001	54	view →
LUAD	DFS	Quartile	All	0.741	0.861	.005	28	view →
COAD	DFS	Quartile	II,III,IV	0.401	0.855	.003	25	view →
ACC	DFS	Tertile	All	0.322	0.816	.019	22	view →
UVM	DFS	Median	III,IV	0.646	0.270	.006	19	view →
BLCA	OS	Median	IV	0.501	0.672	.009	12	view →
LUSC	DFS	Tertile	III,IV	0.421	0.855	.030	12	view →
PRAD	DFS	Median	All	0.724	0.864	.015	10	view →
BRCA	DFS	Quartile	IV	1.000	0.340	.007	9	view →
HNSC	OS	Tertile	III,IV	0.331	0.659	.009	8	view →
DLBC	DFS	Quartile	II,III,IV	0.553	1.000	.023	7	view →
KICH	OS	Median	III,IV	0.378	0.894	.016	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

NPRL3–LIHC (DFS)

Open the LIHC breakdown →